- Home
- SFST vs RIGL Comparison
SFST vs RIGL Comparison
Compare SFST & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- RIGL
- Stock Information
- Founded
- SFST 1999
- RIGL 1996
- Country
- SFST United States
- RIGL United States
- Employees
- SFST N/A
- RIGL N/A
- Industry
- SFST Major Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SFST Finance
- RIGL Health Care
- Exchange
- SFST Nasdaq
- RIGL Nasdaq
- Market Cap
- SFST 285.9M
- RIGL 335.5M
- IPO Year
- SFST 1999
- RIGL 2000
- Fundamental
- Price
- SFST $39.07
- RIGL $18.98
- Analyst Decision
- SFST Buy
- RIGL Buy
- Analyst Count
- SFST 1
- RIGL 5
- Target Price
- SFST $43.00
- RIGL $36.40
- AVG Volume (30 Days)
- SFST 17.8K
- RIGL 206.5K
- Earning Date
- SFST 07-21-2025
- RIGL 08-05-2025
- Dividend Yield
- SFST N/A
- RIGL N/A
- EPS Growth
- SFST 37.29
- RIGL N/A
- EPS
- SFST 2.25
- RIGL 2.08
- Revenue
- SFST $97,501,000.00
- RIGL $203,077,000.00
- Revenue This Year
- SFST $4.07
- RIGL $14.41
- Revenue Next Year
- SFST $8.99
- RIGL $15.97
- P/E Ratio
- SFST $17.51
- RIGL $9.41
- Revenue Growth
- SFST 11.95
- RIGL 70.16
- 52 Week Low
- SFST $28.74
- RIGL $8.10
- 52 Week High
- SFST $45.91
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- SFST 58.48
- RIGL 45.79
- Support Level
- SFST $39.35
- RIGL $18.24
- Resistance Level
- SFST $40.00
- RIGL $19.38
- Average True Range (ATR)
- SFST 0.86
- RIGL 0.77
- MACD
- SFST 0.13
- RIGL -0.04
- Stochastic Oscillator
- SFST 78.44
- RIGL 43.64
About SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.